RGNT· Health Care› Medical Instruments & Supplies

Regentis Biomaterials Ltd.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Regentis Biomaterials is in Stage 4, the downtrend phase, now in week 5 (since Sep 22, 2026). It closed at $1.40, below its 200-day average, which is falling.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. More about the company

$1.40

-6.04% today

$9.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is RGNT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-12-04 → 2026-10-22

S? 42w

S4 4w

2025-12-042026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 4w current

Total tracked: 46 weeks across 2 stage runs.

RGNT among Medical Instruments & Supplies48th of 51 by relative strength

All 51 →

Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	PLSEPulse Biosciences, Inc	Stage 2 · wk 34	98	+1.3%
2	PDEXPro-Dex, Inc.	Stage 2 · wk 36	97	−13.3%
3	HBIOHarvard Bioscience, Inc.	Stage 2 · wk 11	95	+3.6%
4	ATRCAtriCure, Inc.	Stage 2 · wk 10	89	−1.1%
5	WSTWest Pharmaceutical Services, Inc.	Stage 2 · wk 24	82	+4.8%
6	BDXBecton, Dickinson and Company	Stage 2 · wk 11	81	+9.8%
7	ICUIICU Medical, Inc.	Stage 3 · wk 1	81	+3.1%
8	OSUROraSure Technologies, Inc.	Stage 3 · wk 8	75	−4.8%
…48	RGNTRegentis Biomaterials Ltd.	Stage 4 · wk 5	—	−33.3%

vs 52W High

—

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-54.5%

200 DMA: $3.08 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.03x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-33.3%

-28.6%

-54.5%

YTD

-79.2%

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 1.03x

2026-10-21S4

Wk 5 · Vol 0.28x

2026-10-20S4

Wk 5 · Vol 0.28x

2026-10-19S4

Wk 4 · Vol 0.72x

2026-10-16S4

Wk 4 · Vol 0.47x

2026-10-15S4

Wk 4 · Vol 0.27x

2026-10-14S4

Wk 4 · Vol 2.56x

2026-10-13S4

Wk 4 · Vol 0.62x

2026-10-12S4

Wk 3 · Vol 0.65x

2026-10-09S4

Wk 3 · Vol 0.39x

2026-10-08S4

Wk 3 · Vol 3.17x

2026-10-07S4

Wk 3 · Vol 0.30x

Moving averages & range

50 DMA

$1.87

200 DMA

$3.08

52W High

—

52W Low

—

5D Low

$1.40

Resistance levels (recent highs)

20d High

$1.98

60d High

$2.23

120d High

$9.40

250d High

—

Next resistance

+41.4%

to 20d High

Dividend Yield

0.00%

P/B 1.3

Regentis Biomaterials: quick answers

What stage is Regentis Biomaterials in?

As of Oct 22, 2026, Regentis Biomaterials (RGNT) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 22, 2026 and is in week 5. What the four stages mean

Is Regentis Biomaterials in an uptrend?

No. Regentis Biomaterials is in a Stage 4 downtrend. It trades 54.5% below its 200-day average, which is falling.

How has Regentis Biomaterials performed over the past year?

As of Oct 22, 2026, Regentis Biomaterials is down 79.2% so far in 2026.

Which sector and industry is Regentis Biomaterials in?

Regentis Biomaterials is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.